计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| R125138-10mg |
10mg |
现货 ![]() |
| |
| R125138-50mg |
50mg |
现货 ![]() |
| |
| R125138-250mg |
250mg |
现货 ![]() |
| |
| R125138-1g |
1g |
现货 ![]() |
| |
| R125138-5g |
5g |
现货 ![]() |
| |
| R125138-25g |
25g |
现货 ![]() |
|
| 别名 | 利伐沙班 |
|---|---|
| 英文别名 | B01AF01 | 1429742-50-6 | 2-Thiophenecarboxamide, 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxo-4-morpholinyl)phenyl)-5-oxazolidinyl)methyl)- | 2w26 | 9NDF7JZ4M3 | Q420262 | Xarelto | MFCD11974010 | N-Smc-carboxylate | L-Glutatione | RIVAROXABAN [ORANGE BOOK] | MLS0 |
| 规格或纯度 | Moligand™, ≥99% |
| 英文名称 | Rivaroxaban |
| 生化机理 | 利伐沙班(Xarelto;BAY 59-7939)是一种新型口服直接因子 Xa(FXa)抑制剂,目前正处于后期开发阶段,用于预防和治疗血栓栓塞性疾病。利伐沙班(Xarelto;BAY 59-7939)可抑制血栓相关的游离 FXa 活性和凝血酶原酶活性,此外,它还能减少凝血酶的生成。利伐沙班(Xarelto; BAY 59-7939)是一种有效的抗血栓药物。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 凝血因子 X 抑制剂 |
| 产品介绍 |
Rivaroxaban is an oral, direct inhibitor of Factor X, being developed for the prevention and treatment of arterial and venous thrombosis with a Ki of 0.4 nM. Rivaroxaban also inhibits prothrombinase activity (IC50 = 2.1 nM). Rivaroxaban also shows a similar affinity to purified human (IC50 = 0.7 nM) and rabbit Factor X (IC50 = 0.8 nM), but a lesser potency against purified rat Factor X (IC50 = 3.4 nM). Endogenous human and rabbit Factor X in plasma is inhibited to a similar extent by Rivaroxaban (IC50 = 21 nM and 21 nM, respectively), while 14-fold higher concentrations are required in rat plasma (IC50 = 290 nM). Rivaroxaban exhibits high permeability and polarized transport across Caco-2 cells as a substrate of the P-gp, but exhibits no inhibitory effect on P-gp-mediated drμg transport up to concentrations of 100 μM in vitro. Rivaroxaban is an oral, direct inhibitor of Factor X, being developed for the prevention and treatment of arterial and venous thrombosis with a Ki of 0.4 nM. Rivaroxaban also inhibits prothrombinase activity (IC50 = 2.1 nM). Rivaroxaban also shows a similar affinity to purified human (IC50 = 0.7 nM) and rabbit Factor X (IC50 = 0.8 nM), but a lesser potency against purified rat Factor X (IC50 = 3.4 nM). Endogenous human and rabbit Factor X in plasma is inhibited to a similar extent by Rivaroxaban (IC50 = 21 nM and 21 nM, respectively), while 14-fold higher concentrations are required in rat plasma (IC50 = 290 nM). Rivaroxaban exhibits high permeability and polarized transport across Caco-2 cells as a substrate of the P-gp, but exhibits no inhibitory effect on P-gp-mediated drug transport up to concentrations of 100 μM in vitro. |
| 纯度 | ≥99% |
| ALogP | 2.5 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504765023 |
|---|---|
| EC号 | 685-132-2 |
| 分子类型 | 小分子 |
| IIUPAC Name | 5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]thiophene-2-carboxamide |
| INCHI | 1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1 |
| InChi Key | KGFYHTZWPPHNLQ-AWEZNQCLSA-N |
| Smiles | C1COCC(=O)N1C2=CC=C(C=C2)N3CC(OC3=O)CNC(=O)C4=CC=C(S4)Cl |
| Isomeric SMILES | C1COCC(=O)N1C2=CC=C(C=C2)N3C[C@@H](OC3=O)CNC(=O)C4=CC=C(S4)Cl |
| 关联CAS | 366789-02-8 |
| PubChem CID | 9875401 |
| MeSH Entry Terms | 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide;BAY 59 7939;BAY 59-7939;BAY 597939;rivaroxaban;xarelto |
| 分子量 | 435.88 |
| 溶解性 | DMSO 87 mg/mL Ethanol <1 mg/mL |
|---|---|
| 比旋光度 | [α]/D -34 to -44, c = 0.3 in DMSO |
| 熔点 | 230 °C |
| 分子量 | 435.900 g/mol |
| XLogP3 | 2.500 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 6 |
| 可旋转键计数Rotatable Bond Count | 5 |
| 精确质量Exact Mass | 435.066 Da |
| 单同位素质量Monoisotopic Mass | 435.066 Da |
| 拓扑极表面积Topological Polar Surface Area | 116.000 Ų |
| 重原子数Heavy Atom Count | 29 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 645.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 1 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS09 |
|---|---|
| 信号词 | Warning |
| 危险声明 |
H411: 对水生生物有毒并具有长期持续影响 |
| 预防措施声明 |
P273: 避免释放到环境中。 P391: 收集溢出物 P501: 将内容物/容器处理到。。。 |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | R125138 | |
| 分析证书 | R125138 | |
| 分析证书 | R125138 | |
| 分析证书 | R125138 | |
| 分析证书 | R125138 | |
| 分析证书 | R125138 | |
| 分析证书 | R125138 | |
| 分析证书 | R125138 | |
| 分析证书 | R125138 | |
| 分析证书 | R125138 | |
| 分析证书 | R125138 | |
| 分析证书 | R125138 | |
| 分析证书 | R125138 | |
| 分析证书 | R125138 | |
| 分析证书 | R125138 | |
| 分析证书 | R125138 | |
| 分析证书 | R125138 |
| 1. Bosch J, Eikelboom JW, Connolly SJ, Bruns NC, Lanius V, Yuan F, Misselwitz F, Chen E, Diaz R, Alings M et al.. (2017) Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial.. Can J Cardiol, 33 (8): (1027-1035). [PMID:28754388] |
| 2. Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K et al.. (2018) Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.. Lancet, 391 (10117): (219-229). [PMID:29132880] |
| 3. Ru Li, Xuan Zou, Pan Luan, Xiaokun Liu, Ning Wang, Qian Wang, Huashi Guan, Zhe Xu. (2022) Direct Determination of Enzymes in Dried Blood Spots by High-Performance Liquid Chromatography – Mass Spectrometry (HPLC-MS) for the Screening of Antithrombotic Agents. ANALYTICAL LETTERS, [10.1080/00032719.2022.2053700] |
| 4. Xu Wang, Dai-Yan Zhang, Shi-Jun Yin, Hui Jiang, Min Lu, Feng-Qing Yang, Yuan-Jia Hu. (2021) Screening of Potential Thrombin and Factor Xa Inhibitors from the Danshen–Chuanxiong Herbal Pair through a Spectrum–Effect Relationship Analysis. MOLECULES, 26 (23): (7293). [PMID:34885877] [10.3390/molecules26237293] |
| 5. Yang Yi-Yao, Wu Zhao-Yu, Xia Fang-Bo, Zhang Hao, Wang Xu, Gao Jian-Li, Yang Feng-Qing, Wan Jian-Bo. (2020) Characterization of thrombin/factor Xa inhibitors in Rhizoma Chuanxiong through UPLC-MS-based multivariate statistical analysis. Chinese Medicine, 15 (1): (1-14). [PMID:32874198] [10.1186/s13020-020-00376-0] |
| 6. Yang Yi-Yao, Wu Zhao-Yu, Zhang Hao, Yin Shi-Jun, Xia Fang-Bo, Zhang Qian, Wan Jian-Bo, Gao Jian-Li, Yang Feng-Qing. (2020) LC–MS-based multivariate statistical analysis for the screening of potential thrombin/factor Xa inhibitors from Radix Salvia Miltiorrhiza. Chinese Medicine, 15 (1): (1-13). [PMID:32351617] [10.1186/s13020-020-00320-2] |
| 7. Zhe Xu, Ruonan Liu, Huashi Guan. (2017) Dual-target inhibitor screening against thrombin and factor Xa simultaneously by mass spectrometry. ANALYTICA CHIMICA ACTA, 990 (1). [PMID:29029731] [10.1016/j.aca.2017.07.063] |